Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed stage IV prostate cancer (any T, any N, M1, any G; D3)
• Clinical evidence of metastatic disease in bone or soft tissue
• Her2/neu-positive (2+ and 3+) by immunochemistry or fluorescent in situ hybridization
• Androgen-independent
• * Serum PSA at least 10 ng/mL that has risen on 3 successive evaluations after prior hormonal therapy
• * At least 1 month since prior antiandrogen therapy (e.g., flutamide, bicalutamide, or nilutamide) and rising PSA levels with 1 of the 2 rising PSA levels, measured at least 2 weeks apart, after antiandrogen withdrawal
• Bone only disease and elevated PSA alone allowed
• LHRH analog therapy must continue in patients who have not had prior orchiectomy and have castrate levels of testosterone
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• SWOG 0-2
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• WBC at least 3,500/mm3
• Absolute granulocyte count at least 1,800/mm3
• Platelet count at least lower limit of normal (LLN)
• Hepatic:
• Bilirubin no greater than 2 times upper limit of normal (ULN)
• SGOT no greater than 2 times ULN
• Renal:
• Creatinine no greater than 1.6 mg/dL
• Creatinine clearance at least 50 mL/min
• Cardiovascular:
• Ejection fraction more than 50% or more than LLN by MUGA scan or 2-D echocardiogram
• No symptomatic coronary artery disease
• No active ischemia on EKG
• Other:
• Fertile patients must use effective contraception
• No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No concurrent biologic therapy
• Chemotherapy:
• No more than one prior nonanthracycline chemotherapy regimen (including suramin)
• Endocrine therapy:
• See Disease Characteristics
• No concurrent corticosteroids as antiemetic
• Radiotherapy:
• At least 4 weeks since prior radiotherapy
• At least 3 months since prior strontium chloride Sr 89 and recovered
• No concurrent radiotherapy to measurable lesions
• Surgery:
• See Disease Characteristics